melatonin has been researched along with Cardiovascular Stroke in 80 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The MARIA trial tests a novel pharmacologic agent, melatonin, in patients with acute myocardial infarction and the hypothesis that it will confer cardioprotection against ischemia-reperfusion injury." | 9.12 | A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with An ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, MJ; Jimenez-Sosa, A; Kaski, JC; Reiter, RJ, 2007) |
| "Melatonin confers protection against myocardial injury by reducing inflammation and inhibiting apoptosis." | 8.31 | Melatonin attenuates inflammation and cardiac dysfunction in myocardial infarction by regulating the miRNA-200b-3p/high mobility group box chromosomal protein 1 axis. ( Huo, JL; Liu, ZH; Ren, K; Wu, F, 2023) |
| "Melatonin may protect against HS-induced myocardial injury in male rats by mitigating oxidative stress and inflammation." | 7.88 | Melatonin provides protection against heat stroke-induced myocardial injury in male rats. ( Chang, CP; Chao, CM; Lin, CH; Lin, MT; Lin, S; Lin, X; Liu, L; Wen, S; Ye, Z; Zhao, T; Zuo, D, 2018) |
| "Low circulating melatonin levels predict poor outcome in patients with ST-segment elevation myocardial infarction (STEMI)." | 7.79 | Global left ventricular longitudinal strain is associated with decreased melatonin levels in patients with acute myocardial infarction: a two-dimensional speckle tracking study. ( Abreu-Gonzalez, P; Arroyo-Ucar, E; Avanzas, P; Dominguez-Rodriguez, A; Reiter, RJ, 2013) |
| "The vasopressin and oxytocin content of the hypothalamus and neurohypophysis, as well as their plasma levels, were radioimmunoassayed in sham-operated or pinealectomized rats with left coronary artery ligation (CAL)-evoked myocardial infarction as well as under melatonin treatment." | 7.78 | Function of the hypothalamo-neurohypophysial system in rats with myocardial infarction is modified by melatonin. ( Ciosek, J; Drobnik, J, 2012) |
| "As experimental studies suggest that melatonin is cardioprotective after myocardial infarction (MI), this study sought to investigate the relationships between circulating levels of melatonin and left ventricular (LV) remodelling in patients after acute MI." | 7.78 | Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. ( Abreu-Gonzalez, P; Arroyo-Ucar, E; Dominguez-Rodriguez, A; Reiter, RJ, 2012) |
| "The present study was designed to investigate the cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats by studying myocyte injury markers, antioxidant defense system, serum and heart lipid profile, inflammatory markers, electrocardiographic and histopathological changes." | 7.76 | Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. ( Balaraman, R; Patel, V; Upaganlawar, A; Zalawadia, R, 2010) |
| "We examined the time course of changes in the synthesis and levels of endogenous melatonin and in the expression of MT(1) and MT(2) melatonin receptors 1 day, 2 and 4 wk after myocardial infarction (MI) in rats." | 7.74 | The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. ( Ilves, M; Leskinen, H; Mänttäri, S; Ruskoaho, H; Saarela, S; Sallinen, P; Vakkuri, O, 2007) |
| "The aims of the present study were to characterize the day/night variation of matrix metalloproteinase (MMP)-9 in patients who have developed ST-segment elevation myocardial infarction (STEMI), in response to light/dark differences in circulating melatonin and to assess whether melatonin, a day/night variation regulator, modulates the nocturnal inflammatory changes in patients who have STEMI." | 7.74 | Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, MJ; Reiter, RJ, 2007) |
| "We evaluated the possible relation between circulating levels of nocturnal melatonin, C-reactive protein, and the development of adverse cardiovascular events in patients with ST-segment elevation myocardial infarction." | 7.73 | Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, M; Reiter, RJ, 2006) |
| "The dose- and time dependence of melatonin and the effective window of melatonin administration were determined in a mouse model of myocardial infarction." | 7.72 | Protective effect of melatonin on myocardial infarction. ( Chen, Z; Chua, BH; Chua, CC; Gao, J; Hamdy, RC, 2003) |
| "The current findings suggest that the circadian secretion of melatonin may be responsible at least in part for light/dark variations of endogenous interleukin-6 production in patients with acute myocardial infarction." | 7.72 | Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. ( Abreu-Gonzalez, P; de la Rosa, A; Dominguez-Rodriguez, A; Ferrer, J; Garcia, M; Reiter, RJ; Vargas, M, 2004) |
| "Melatonin has cardioprotective properties via its direct free radical scavenging and its indirect antioxidant activity." | 6.48 | The role of melatonin in acute myocardial infarction. ( Abreu-Gonzalez, P; Avanzas, P; Dominguez-Rodriguez, A, 2012) |
| "Melatonin is an indoleamine secreted by the pineal gland and controlled by endogenous circadian oscillators within the suprachiasmatic nucleus, which is closely associated with light/dark cycle." | 5.72 | Melatonin improves cardiac remodeling and brain-heart sympathetic hyperactivation aggravated by light disruption after myocardial infarction. ( Jiang, H; Jiao, L; Li, Z; Liu, Z; Nie, L; Wang, Y; Xu, X; Yu, Z; Zhang, S; Zhou, H; Zhou, L; Zhou, Y, 2022) |
| "Melatonin has been shown to protect the heart against myocardial injury through mitigating oxidative stress, reducing apoptosis, inhibiting mitochondrial fission, etc." | 5.62 | Melatonin promotes cardiomyocyte proliferation and heart repair in mice with myocardial infarction via miR-143-3p/Yap/Ctnnd1 signaling pathway. ( Bamba, D; Cai, BZ; Gong, R; Han, ZB; Li, SN; Liu, SZ; Ma, WY; Pan, ZW; Song, RJ; Sun, HY; Wang, N; Wang, XX; Xu, BB; Xu, Y; Yang, F; Ye, DY; Yu, MX; Yu, Y, 2021) |
| "Melatonin was capable to inhibit the increase of miR-98 level by H2O2 in CPCs." | 5.48 | Pre-Treatment with Melatonin Enhances Therapeutic Efficacy of Cardiac Progenitor Cells for Myocardial Infarction. ( Bi, C; Cai, B; Ding, F; Du, Z; Han, Z; He, F; Hua, B; Huang, Q; Jin, M; Liu, T; Lu, Y; Ma, W; Wang, X; Yang, F; Yu, Y; Yuan, Y; Zhang, L, 2018) |
| " A total of 20 landrace pigs were randomized to a dosage of 200 mg (0." | 5.43 | Effects of intracoronary melatonin on ischemia-reperfusion injury in ST-elevation myocardial infarction. ( Aarøe, J; Ekeløf, SV; Gögenur, I; Halladin, NL; Jensen, SE; Kjærgaard, B; Rosenberg, J; Simonsen, CW; Zaremba, T, 2016) |
| "Melatonin is a highly potent and efficient radical scavenger." | 5.31 | Decreased nocturnal melatonin levels during acute myocardial infarction. ( Abreu-González, P; de Armas-Trujillo, D; Domínguez-Rodríguez, A; García, MJ; Marrero, F; Sanchez, J, 2002) |
| "The MARIA trial tests a novel pharmacologic agent, melatonin, in patients with acute myocardial infarction and the hypothesis that it will confer cardioprotection against ischemia-reperfusion injury." | 5.12 | A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with An ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, MJ; Jimenez-Sosa, A; Kaski, JC; Reiter, RJ, 2007) |
| "Melatonin confers protection against myocardial injury by reducing inflammation and inhibiting apoptosis." | 4.31 | Melatonin attenuates inflammation and cardiac dysfunction in myocardial infarction by regulating the miRNA-200b-3p/high mobility group box chromosomal protein 1 axis. ( Huo, JL; Liu, ZH; Ren, K; Wu, F, 2023) |
| "Treatment with melatonin at all time points alleviated cardiac I/R injury to a similar extent, quantified by reduction in infarct size, arrhythmia score, LV dysfunction, cardiac mitochondrial dysfunction, imbalance of mitochondrial dynamics, excessive mitophagy, and a decreased Bax/Bcl2 ratio." | 4.02 | Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Singhanat, K, 2021) |
| "Melatonin may protect against HS-induced myocardial injury in male rats by mitigating oxidative stress and inflammation." | 3.88 | Melatonin provides protection against heat stroke-induced myocardial injury in male rats. ( Chang, CP; Chao, CM; Lin, CH; Lin, MT; Lin, S; Lin, X; Liu, L; Wen, S; Ye, Z; Zhao, T; Zuo, D, 2018) |
| "To measure blood IL-6, IL-10, creatinine levels, calcium, sodium and potassium in blood and saliva, melatonin in urine of patients with acute coronary syndrome without ST segment elevation for the prediction of the clinical course at the post-hospital stage." | 3.83 | [ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION: POSSIBILITIES FOR PREDICTING THE CLINICAL COURSE AT THE POST-HOSPITAL (6 AND 12 MONTHS) STAGE]. ( , 2016) |
| "The effect of nimodipine, mexidol, melatonin, afobazole, 5-hydroxy-adanamtan-2-one, and GABA conjugates with arachidonic acid and docosahexaenoyl dopamine on the cerebral circulation has been studied in intact rats and those with global transient cerebral ischemia, experimental myocardial infarction, and combined vascular pathology of brain and heart." | 3.80 | [Cerebrovascular pharmacology of separate and combined vascular pathology of brain and heart]. ( Gan'shina, TS; Gnezdilova, AV; Gorbunov, AA; Khaĭlov, NA; Kurdiumov, IN; Lebedeva, MA; Maslennikov, DV; Mirzoian, RS, 2014) |
| "Low circulating melatonin levels predict poor outcome in patients with ST-segment elevation myocardial infarction (STEMI)." | 3.79 | Global left ventricular longitudinal strain is associated with decreased melatonin levels in patients with acute myocardial infarction: a two-dimensional speckle tracking study. ( Abreu-Gonzalez, P; Arroyo-Ucar, E; Avanzas, P; Dominguez-Rodriguez, A; Reiter, RJ, 2013) |
| "As experimental studies suggest that melatonin is cardioprotective after myocardial infarction (MI), this study sought to investigate the relationships between circulating levels of melatonin and left ventricular (LV) remodelling in patients after acute MI." | 3.78 | Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. ( Abreu-Gonzalez, P; Arroyo-Ucar, E; Dominguez-Rodriguez, A; Reiter, RJ, 2012) |
| "The vasopressin and oxytocin content of the hypothalamus and neurohypophysis, as well as their plasma levels, were radioimmunoassayed in sham-operated or pinealectomized rats with left coronary artery ligation (CAL)-evoked myocardial infarction as well as under melatonin treatment." | 3.78 | Function of the hypothalamo-neurohypophysial system in rats with myocardial infarction is modified by melatonin. ( Ciosek, J; Drobnik, J, 2012) |
| "The present study was designed to investigate the cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats by studying myocyte injury markers, antioxidant defense system, serum and heart lipid profile, inflammatory markers, electrocardiographic and histopathological changes." | 3.76 | Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. ( Balaraman, R; Patel, V; Upaganlawar, A; Zalawadia, R, 2010) |
| "The aims of the present study were to characterize the day/night variation of matrix metalloproteinase (MMP)-9 in patients who have developed ST-segment elevation myocardial infarction (STEMI), in response to light/dark differences in circulating melatonin and to assess whether melatonin, a day/night variation regulator, modulates the nocturnal inflammatory changes in patients who have STEMI." | 3.74 | Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, MJ; Reiter, RJ, 2007) |
| "We examined the time course of changes in the synthesis and levels of endogenous melatonin and in the expression of MT(1) and MT(2) melatonin receptors 1 day, 2 and 4 wk after myocardial infarction (MI) in rats." | 3.74 | The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. ( Ilves, M; Leskinen, H; Mänttäri, S; Ruskoaho, H; Saarela, S; Sallinen, P; Vakkuri, O, 2007) |
| "We evaluated the possible relation between circulating levels of nocturnal melatonin, C-reactive protein, and the development of adverse cardiovascular events in patients with ST-segment elevation myocardial infarction." | 3.73 | Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, M; Reiter, RJ, 2006) |
| "The dose- and time dependence of melatonin and the effective window of melatonin administration were determined in a mouse model of myocardial infarction." | 3.72 | Protective effect of melatonin on myocardial infarction. ( Chen, Z; Chua, BH; Chua, CC; Gao, J; Hamdy, RC, 2003) |
| "The current findings suggest that the circadian secretion of melatonin may be responsible at least in part for light/dark variations of endogenous interleukin-6 production in patients with acute myocardial infarction." | 3.72 | Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. ( Abreu-Gonzalez, P; de la Rosa, A; Dominguez-Rodriguez, A; Ferrer, J; Garcia, M; Reiter, RJ; Vargas, M, 2004) |
| "Melatonin is a hormone that is produced by the pineal gland, and it plays an important role in regulating many physiological functions in human body." | 2.58 | Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Singhanat, K, 2018) |
| "Melatonin has cardioprotective properties via its direct free radical scavenging and its indirect antioxidant activity." | 2.48 | The role of melatonin in acute myocardial infarction. ( Abreu-Gonzalez, P; Avanzas, P; Dominguez-Rodriguez, A, 2012) |
| "Melatonin is an indoleamine secreted by the pineal gland and controlled by endogenous circadian oscillators within the suprachiasmatic nucleus, which is closely associated with light/dark cycle." | 1.72 | Melatonin improves cardiac remodeling and brain-heart sympathetic hyperactivation aggravated by light disruption after myocardial infarction. ( Jiang, H; Jiao, L; Li, Z; Liu, Z; Nie, L; Wang, Y; Xu, X; Yu, Z; Zhang, S; Zhou, H; Zhou, L; Zhou, Y, 2022) |
| "Melatonin has been shown to protect the heart against myocardial injury through mitigating oxidative stress, reducing apoptosis, inhibiting mitochondrial fission, etc." | 1.62 | Melatonin promotes cardiomyocyte proliferation and heart repair in mice with myocardial infarction via miR-143-3p/Yap/Ctnnd1 signaling pathway. ( Bamba, D; Cai, BZ; Gong, R; Han, ZB; Li, SN; Liu, SZ; Ma, WY; Pan, ZW; Song, RJ; Sun, HY; Wang, N; Wang, XX; Xu, BB; Xu, Y; Yang, F; Ye, DY; Yu, MX; Yu, Y, 2021) |
| "Melatonin treatment caused a significant reduction in infarct size in hearts from both control and diet groups." | 1.56 | Mitochondrial Oxidative Phosphorylation Function and Mitophagy in Ischaemic/Reperfused Hearts from Control and High-Fat Diet Rats: Effects of Long-Term Melatonin Treatment. ( Dhanabalan, K; Huisamen, B; Lochner, A; Mzezewa, S, 2020) |
| "Melatonin is a multifunctional indolamine and has a cardioprotective role in a variety of cardiovascular processes via antioxidant, anti-inflammatory, antihypertensive, antithrombotic, and antilipemic effects." | 1.51 | Plasma levels of melatonin in dilated cardiomyopathy. ( Kobayashi, A; Kunii, H; Misaka, T; Nakazato, K; Oikawa, M; Sato, T; Sugimoto, K; Takeishi, Y; Yamaki, T; Yokokawa, T; Yoshihisa, A, 2019) |
| "Melatonin has been used as a powerful endogenous antioxidant to protect cells from oxidative injury." | 1.48 | Poly(Lactide-Co-Glycolide)-Monomethoxy-Poly-(Polyethylene Glycol) Nanoparticles Loaded with Melatonin Protect Adipose-Derived Stem Cells Transplanted in Infarcted Heart Tissue. ( Cao, F; Chen, Y; Guo, W; Huang, X; Li, J; Li, S; Ma, Q; Yang, J; Zhou, H, 2018) |
| "Melatonin was capable to inhibit the increase of miR-98 level by H2O2 in CPCs." | 1.48 | Pre-Treatment with Melatonin Enhances Therapeutic Efficacy of Cardiac Progenitor Cells for Myocardial Infarction. ( Bi, C; Cai, B; Ding, F; Du, Z; Han, Z; He, F; Hua, B; Huang, Q; Jin, M; Liu, T; Lu, Y; Ma, W; Wang, X; Yang, F; Yu, Y; Yuan, Y; Zhang, L, 2018) |
| " A total of 20 landrace pigs were randomized to a dosage of 200 mg (0." | 1.43 | Effects of intracoronary melatonin on ischemia-reperfusion injury in ST-elevation myocardial infarction. ( Aarøe, J; Ekeløf, SV; Gögenur, I; Halladin, NL; Jensen, SE; Kjærgaard, B; Rosenberg, J; Simonsen, CW; Zaremba, T, 2016) |
| "Melatonin has been proven to have a regulatory influence on collagen accumulation in different types of wound." | 1.39 | Melatonin-induced augmentation of collagen deposition in cultures of fibroblasts and myofibroblasts is blocked by luzindole--a melatonin membrane receptors inhibitor. ( Ciosek, J; Drobnik, J; Hrabec, E; Olczak, S; Owczarek, K; Piera, L; Tosik, D, 2013) |
| " Our data demonstrate that both melatonin and resveratrol, as found in red wine, protect the heart in an experimental model of myocardial infarction via the SAFE pathway." | 1.37 | Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. ( Lacerda, L; Lamont, KT; Lecour, S; Opie, LH; Somers, S, 2011) |
| "Melatonin has virtually no toxicity which raises the possibility of this indole being a therapeutic treatment for ischemic heart disease." | 1.36 | Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. ( Bandyopadhyay, A; Bandyopadhyay, D; Basu, A; Chattopadhyay, A; Ghosh, AK; Mitra, E; Mukherjee, D; Reiter, RJ; Roy, SG, 2010) |
| "Cells isolated from the heart scar were identified as myofibroblasts." | 1.36 | Melatonin augments expression of the procollagen α1 (I) and α1 (III) genes in the infarcted heart scar of pinealectomized rats. ( Drobnik, J; Hrabec, E; Hrabec, Z; Olczak, S; Owczarek, K, 2010) |
| "Melatonin treatment significantly improves the functional recovery of Langerdoff hearts on reperfusion, reduces the infarct size, and decreases necrotic damage as shown by the reduced release of lactate dehydrogenase." | 1.35 | Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. ( Colantuono, G; Di Venosa, N; Fiore, T; Moro, N; Paradies, G; Petrosillo, G; Ruggiero, FM; Tiravanti, E, 2009) |
| "Melatonin has potent cardioprotective properties." | 1.35 | Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions. ( Genade, S; Genis, A; Huisamen, B; Lochner, A; Ytrehus, K, 2008) |
| "Cells isolated from the heart scar were identified as myofibroblasts." | 1.35 | Regulatory influence of melatonin on collagen accumulation in the infarcted heart scar. ( Dabrowski, R; Drobnik, J; Jakubowski, L; Karbownik-Lewińska, M; Olczak, S; Szczepanowska, A; Słotwińska, D, 2008) |
| "The melatonin receptor was manipulated using luzindole and N-acetyltryptamine." | 1.33 | Short- and long-term effects of melatonin on myocardial post-ischemic recovery. ( Davids, A; Genade, S; Lochner, A; Moolman, JA; Ytrehus, K, 2006) |
| "Reduction in the synthesis or bioavailability of nitric oxide plays a significant role in the development of myocardial infarction and hypertension." | 1.33 | Nitric oxide synthase inhibition in rats: melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size. ( Aksulu, HE; Deniz, E; Sahna, E, 2006) |
| "Melatonin is a well-known antioxidant and free radical scavenger." | 1.33 | Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. ( Acet, A; Parlakpinar, H; Sahna, E; Turkoz, Y, 2005) |
| "As melatonin levels have been reported to decrease with age, melatonin replacement therapy may attenuate I/R-induced myocardial injury, especially in older patients." | 1.31 | Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. ( Acet, A; Olmez, E; Ozer, MK; Sahna, E, 2002) |
| "Melatonin is a highly potent and efficient radical scavenger." | 1.31 | Decreased nocturnal melatonin levels during acute myocardial infarction. ( Abreu-González, P; de Armas-Trujillo, D; Domínguez-Rodríguez, A; García, MJ; Marrero, F; Sanchez, J, 2002) |
| "Melatonin has been found to be effective in protecting against pathological states due to reactive oxygen species release." | 1.31 | Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. ( Demenge, P; Godin-Ribuot, D; Joyeux, M; Lagneux, C; Ribuot, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (28.75) | 29.6817 |
| 2010's | 44 (55.00) | 24.3611 |
| 2020's | 13 (16.25) | 2.80 |
| Authors | Studies |
|---|---|
| Veiga, ECA | 1 |
| Simões, RDS | 1 |
| Caviola, LL | 1 |
| Abreu, LC | 1 |
| Cavalli, RC | 1 |
| Cipolla-Neto, J | 1 |
| Baracat, EC | 1 |
| Soares Júnior, JM | 1 |
| Wang, Y | 6 |
| Zhang, S | 2 |
| Ma, Y | 1 |
| Xiang, A | 1 |
| Sun, H | 1 |
| Song, J | 1 |
| Yang, W | 1 |
| Li, X | 4 |
| Xu, H | 1 |
| Jiao, L | 1 |
| Liu, Z | 3 |
| Zhou, Y | 1 |
| Zhou, H | 2 |
| Xu, X | 1 |
| Li, Z | 1 |
| Yu, Z | 1 |
| Nie, L | 1 |
| Zhou, L | 1 |
| Jiang, H | 1 |
| Wang, SJ | 3 |
| Fang, SH | 3 |
| Yu, B | 3 |
| Maity, J | 3 |
| Dey, T | 3 |
| Banerjee, A | 3 |
| Chattopadhyay, A | 4 |
| Das, AR | 3 |
| Bandyopadhyay, D | 4 |
| Böhm, A | 1 |
| Lauko, V | 1 |
| Dostalova, K | 1 |
| Balanova, I | 1 |
| Varga, I | 1 |
| Bezak, B | 1 |
| Jajcay, N | 1 |
| Moravcik, R | 1 |
| Lazurova, L | 1 |
| Slezak, P | 1 |
| Mojto, V | 1 |
| Kollarova, M | 1 |
| Petrikova, K | 1 |
| Danova, K | 1 |
| Zeman, M | 1 |
| Zhang, H | 2 |
| Li, S | 2 |
| Jin, Y | 1 |
| Liu, ZH | 1 |
| Wu, F | 1 |
| Ren, K | 1 |
| Huo, JL | 1 |
| Hosseini, L | 1 |
| Vafaee, MS | 1 |
| Badalzadeh, R | 1 |
| Lu, L | 2 |
| Ma, J | 1 |
| Sun, M | 1 |
| Wang, X | 2 |
| Gao, E | 4 |
| Ren, J | 1 |
| Yang, L | 1 |
| Yang, J | 2 |
| Dhanabalan, K | 1 |
| Mzezewa, S | 1 |
| Huisamen, B | 2 |
| Lochner, A | 3 |
| Ma, WY | 1 |
| Song, RJ | 1 |
| Xu, BB | 1 |
| Xu, Y | 1 |
| Wang, XX | 1 |
| Sun, HY | 1 |
| Li, SN | 1 |
| Liu, SZ | 1 |
| Yu, MX | 1 |
| Yang, F | 2 |
| Ye, DY | 1 |
| Gong, R | 1 |
| Han, ZB | 1 |
| Yu, Y | 2 |
| Bamba, D | 1 |
| Wang, N | 1 |
| Pan, ZW | 1 |
| Cai, BZ | 1 |
| Singhanat, K | 2 |
| Apaijai, N | 2 |
| Jaiwongkam, T | 1 |
| Kerdphoo, S | 1 |
| Chattipakorn, SC | 2 |
| Chattipakorn, N | 2 |
| Dominguez-Rodriguez, A | 19 |
| Abreu-Gonzalez, P | 19 |
| Reiter, RJ | 16 |
| Bulluck, H | 1 |
| Nicholas, J | 1 |
| Crimi, G | 1 |
| White, SK | 1 |
| Ludman, AJ | 1 |
| Pica, S | 1 |
| Raineri, C | 1 |
| Cabrera-Fuentes, HA | 1 |
| Yellon, DM | 2 |
| Rodriguez-Palomares, J | 1 |
| Garcia-Dorado, D | 2 |
| Hausenloy, DJ | 2 |
| Kong, L | 1 |
| Wei, M | 1 |
| Sun, N | 1 |
| Zhu, J | 1 |
| Su, X | 1 |
| Erik Bøtker, H | 1 |
| Davidson, SM | 1 |
| Downey, J | 1 |
| Engel, FB | 1 |
| Jennings, R | 1 |
| Lecour, S | 3 |
| Leor, J | 1 |
| Madonna, R | 1 |
| Ovize, M | 1 |
| Perrino, C | 1 |
| Prunier, F | 1 |
| Schulz, R | 1 |
| Sluijter, JPG | 1 |
| Van Laake, LW | 1 |
| Vinten-Johansen, J | 1 |
| Ytrehus, K | 3 |
| Heusch, G | 1 |
| Ferdinandy, P | 1 |
| Ma, Q | 1 |
| Huang, X | 1 |
| Guo, W | 1 |
| Li, J | 1 |
| Cao, F | 2 |
| Chen, Y | 1 |
| Lin, X | 1 |
| Zhao, T | 1 |
| Lin, CH | 1 |
| Zuo, D | 1 |
| Ye, Z | 1 |
| Lin, S | 1 |
| Wen, S | 1 |
| Liu, L | 1 |
| Lin, MT | 1 |
| Chang, CP | 1 |
| Chao, CM | 1 |
| Ma, W | 1 |
| He, F | 1 |
| Ding, F | 1 |
| Zhang, L | 2 |
| Huang, Q | 1 |
| Bi, C | 1 |
| Hua, B | 1 |
| Yuan, Y | 1 |
| Han, Z | 1 |
| Jin, M | 1 |
| Liu, T | 2 |
| Cai, B | 1 |
| Lu, Y | 1 |
| Du, Z | 2 |
| Ma, S | 2 |
| Dong, Z | 1 |
| Misaka, T | 1 |
| Yoshihisa, A | 1 |
| Yokokawa, T | 1 |
| Sato, T | 1 |
| Oikawa, M | 1 |
| Kobayashi, A | 1 |
| Yamaki, T | 1 |
| Sugimoto, K | 1 |
| Kunii, H | 1 |
| Nakazato, K | 1 |
| Takeishi, Y | 1 |
| Yang, JB | 1 |
| Kang, YM | 1 |
| Zhang, C | 1 |
| Yu, XJ | 1 |
| Chen, WS | 1 |
| Ciosek, J | 3 |
| Drobnik, J | 6 |
| Arroyo-Ucar, E | 2 |
| Avanzas, P | 3 |
| Owczarek, K | 2 |
| Piera, L | 2 |
| Tosik, D | 3 |
| Olczak, S | 5 |
| Hrabec, E | 2 |
| Szczepanowska, A | 3 |
| Zielinska, A | 1 |
| Liberski, PP | 1 |
| Halladin, NL | 3 |
| Busch, SE | 1 |
| Jensen, SE | 2 |
| Hansen, HS | 1 |
| Zaremba, T | 2 |
| Aarøe, J | 2 |
| Rosenberg, J | 2 |
| Gögenur, I | 2 |
| Mirzoian, RS | 1 |
| Gan'shina, TS | 1 |
| Khaĭlov, NA | 1 |
| Gnezdilova, AV | 1 |
| Maslennikov, DV | 1 |
| Kurdiumov, IN | 1 |
| Lebedeva, MA | 1 |
| Gorbunov, AA | 1 |
| Ekeløf, SV | 1 |
| Kjærgaard, B | 1 |
| Simonsen, CW | 1 |
| Garcia-Saiz, Mdel M | 1 |
| Aldea-Perona, A | 1 |
| de la Torre, JM | 1 |
| Garcia-Camarero, T | 1 |
| Consuegra-Sanchez, L | 1 |
| Giblett, JP | 1 |
| West, NEJ | 1 |
| Hoole, SP | 1 |
| Zhu, P | 1 |
| Liu, J | 2 |
| Shi, J | 1 |
| Zhou, Q | 1 |
| Zhang, X | 1 |
| Liu, Q | 1 |
| Guo, Y | 2 |
| Liu, LF | 1 |
| Qian, ZH | 1 |
| Qin, Q | 1 |
| Shi, M | 1 |
| Tao, XM | 1 |
| Zhu, WP | 1 |
| Lamont, K | 1 |
| Nduhirabandi, F | 1 |
| Adam, T | 1 |
| Thomas, DP | 1 |
| Opie, LH | 2 |
| Han, D | 1 |
| Huang, W | 1 |
| Gao, L | 2 |
| Su, T | 1 |
| Li, C | 1 |
| Chen, J | 1 |
| Zhao, YC | 1 |
| Liang, Y | 1 |
| Lin, XH | 1 |
| Tan, YJ | 1 |
| Wu, DD | 1 |
| Li, XZ | 1 |
| Ye, BZ | 1 |
| Kong, FQ | 1 |
| Sheng, JZ | 1 |
| Huang, HF | 1 |
| Pei, H | 1 |
| Du, J | 2 |
| Song, X | 1 |
| He, L | 2 |
| Zhang, Y | 2 |
| Qiu, C | 1 |
| Hou, J | 1 |
| Feng, J | 2 |
| Yang, Y | 3 |
| Hu, J | 1 |
| Fan, Y | 1 |
| Zhang, M | 1 |
| Man, W | 1 |
| Hu, W | 1 |
| Wang, H | 1 |
| Sun, D | 1 |
| Pei, HF | 1 |
| Hou, JN | 1 |
| Wei, FP | 1 |
| Xue, Q | 1 |
| Zhang, F | 1 |
| Peng, CF | 1 |
| Tian, Y | 1 |
| Li, XC | 1 |
| Gao, EH | 1 |
| Yang, YJ | 1 |
| McMullan, CJ | 1 |
| Rimm, EB | 1 |
| Schernhammer, ES | 1 |
| Forman, JP | 1 |
| Baykan, A | 1 |
| Narin, N | 1 |
| Narin, F | 1 |
| Akgün, H | 1 |
| Yavaşcan, S | 1 |
| Saraymen, R | 1 |
| Genade, S | 2 |
| Genis, A | 1 |
| Petrosillo, G | 1 |
| Colantuono, G | 1 |
| Moro, N | 1 |
| Ruggiero, FM | 1 |
| Tiravanti, E | 1 |
| Di Venosa, N | 1 |
| Fiore, T | 1 |
| Paradies, G | 1 |
| Mukherjee, D | 1 |
| Roy, SG | 1 |
| Bandyopadhyay, A | 1 |
| Basu, A | 1 |
| Mitra, E | 1 |
| Ghosh, AK | 1 |
| Hrabec, Z | 1 |
| Patel, V | 1 |
| Upaganlawar, A | 1 |
| Zalawadia, R | 1 |
| Balaraman, R | 1 |
| Jimenez-Sosa, A | 2 |
| Bosa-Ojeda, F | 1 |
| Kaski, JC | 5 |
| Lamont, KT | 1 |
| Somers, S | 1 |
| Lacerda, L | 1 |
| Slotwinska, D | 1 |
| Pieniazek, A | 1 |
| Matczak, K | 1 |
| Koceva-Chyla, A | 1 |
| Ramond, A | 1 |
| Godin-Ribuot, D | 2 |
| Ribuot, C | 2 |
| Totoson, P | 1 |
| Koritchneva, I | 1 |
| Cachot, S | 1 |
| Levy, P | 1 |
| Joyeux-Faure, M | 1 |
| Sahna, E | 3 |
| Acet, A | 2 |
| Ozer, MK | 1 |
| Olmez, E | 1 |
| García, MJ | 1 |
| Sanchez, J | 1 |
| Marrero, F | 1 |
| de Armas-Trujillo, D | 1 |
| Chen, Z | 1 |
| Chua, CC | 1 |
| Gao, J | 1 |
| Hamdy, RC | 1 |
| Chua, BH | 1 |
| Acikel, M | 1 |
| Buyukokuroglu, ME | 1 |
| Aksoy, H | 1 |
| Erdogan, F | 1 |
| Erol, MK | 1 |
| Garcia, M | 1 |
| Ferrer, J | 2 |
| de la Rosa, A | 1 |
| Vargas, M | 2 |
| Parlakpinar, H | 1 |
| Turkoz, Y | 1 |
| Garcia-Gonzalez, M | 3 |
| Ferrer-Hita, J | 1 |
| Lisitsa, GV | 1 |
| Zaslavskaia, RM | 1 |
| Kalinina, EV | 1 |
| Davids, A | 1 |
| Moolman, JA | 1 |
| Deniz, E | 1 |
| Aksulu, HE | 1 |
| Garcia-Gonzalez, MJ | 4 |
| Sallinen, P | 2 |
| Mänttäri, S | 2 |
| Leskinen, H | 2 |
| Ilves, M | 1 |
| Vakkuri, O | 2 |
| Ruskoaho, H | 2 |
| Saarela, S | 2 |
| Samimi-Fard, S | 2 |
| Karbownik-Lewińska, M | 1 |
| Słotwińska, D | 1 |
| Jakubowski, L | 1 |
| Dabrowski, R | 1 |
| Lagneux, C | 1 |
| Joyeux, M | 1 |
| Demenge, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intracoronary Injection of Melatonin for Patients With ST-elevation Myocardial Infarction: a Placebo Controlled Randomized Study[NCT01172171] | Phase 2 | 41 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| The Effect of Remote Ischemic Preconditioning on the Postoperative Liver Function in Living Donor Hepatectomy: a Randomized Clinical Trial[NCT03386435] | 160 participants (Actual) | Interventional | 2016-08-22 | Completed | |||
| A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)[NCT03764020] | Phase 3 | 320 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Association Between Plasma Melatonin and No-reflow[NCT03306303] | 1,700 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Melatonin as an Adjunct in Patients With Acute myocaRdial Infarction Undergoing Primary Angioplasty[NCT00640094] | Phase 2 | 272 participants (Actual) | Interventional | 2013-05-31 | Terminated | ||
| Effects of Melatonin on Reperfusion Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT03303378] | 190 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of delayed recovery of hepatic function (DRHF) were used as surrogate parameters indicating the possible benefits of RIPC. DRHF was defined based on a proposal by the International Study Group of Liver Surgery, as follows: an impaired ability of the liver to maintain its synthetic, excretory, and detoxifying functions, which are characterized by an increased PT INR and concomitant hyperbilirubinemia (considering the normal limits of the local laboratory) on or after postoperative day 5. The normal upper limits of PT and bilirubin in our institutional laboratory were 1.30 INR and 1.2 mg/dL, respectively. If either the PT INR or serum bilirubin concentration was preoperatively elevated, DRHF was defined by an increasing PT INR and increasing serum bilirubin concentration on or after postoperative day 5 (compared with the values of the previous day). (NCT03386435)
Timeframe: postoperative 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| RIPC | 5 |
| Control | 0 |
The serial assessments of routine laboratory values were used as early markers for postoperative liver function. The maximal aspartate aminotransferase level within 7 postoperative days were assessed following RIPC in living donor hepatectomy. (NCT03386435)
Timeframe: within 7 days after operation
| Intervention | IU/L (Mean) |
|---|---|
| RIPC | 145 |
| Control | 152 |
The postoperative liver regeneration index (LRI) at postoperative 1 month ) was used as surrogate parameters indicating the possible benefits of RIPC. The LRI was defined as [(VLR - VFLR)/VFLR)] × 100, where VLR is the volume of the liver remnant and VFLR is the volume of the future liver remnant. Liver volume was calculated by CT volumetry using 3-mm-thick dynamic CT images. The graft weight was subtracted from the total liver volume to define the future liver remnant. (NCT03386435)
Timeframe: 1 month
| Intervention | percentage of liver volume (Mean) |
|---|---|
| RIPC | 83.3 |
| Control | 94.9 |
The serial assessments of routine laboratory values were used as early markers for postoperative liver function. The maximal alanine aminotransferase level within 7 postoperative days were assessed following RIPC in living donor hepatectomy (NCT03386435)
Timeframe: within 7 days after operation
| Intervention | IU/L (Mean) |
|---|---|
| RIPC | 148 |
| Control | 152 |
6 reviews available for melatonin and Cardiovascular Stroke
| Article | Year |
|---|---|
Melatonin and the cardiovascular system in animals: systematic review and meta-analysis.
Topics: Animals; Antioxidants; Blood Pressure; Cardiovascular System; Melatonin; Myocardial Infarction | 2021 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury.
Topics: Animals; Humans; Melatonin; Myocardial Infarction; Myocardial Reperfusion Injury; Protein Kinases; R | 2018 |
Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries.
Topics: Angioplasty, Balloon, Coronary; Animals; Antioxidants; Disease Models, Animal; Female; Humans; Infla | 2015 |
A nested case-control study of the association between melatonin secretion and incident myocardial infarction.
Topics: Adult; Biomarkers; Case-Control Studies; Down-Regulation; Female; Humans; Incidence; Logistic Models | 2017 |
The role of melatonin in acute myocardial infarction.
Topics: Animals; Cardiotonic Agents; Circadian Rhythm; Coronary Artery Disease; Humans; Melatonin; Models, C | 2012 |
3 trials available for melatonin and Cardiovascular Stroke
71 other studies available for melatonin and Cardiovascular Stroke
| Article | Year |
|---|---|
Melatonin protected against myocardial infarction injury in rats through a Sirt6-dependent antioxidant pathway.
Topics: Animals; Antioxidants; Melatonin; Myocardial Infarction; Nitric Oxide Synthase Type III; Rats; Strok | 2022 |
Melatonin improves cardiac remodeling and brain-heart sympathetic hyperactivation aggravated by light disruption after myocardial infarction.
Topics: Humans; Melatonin; Myocardial Infarction; Pineal Gland; Suprachiasmatic Nucleus; Ventricular Remodel | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
[Research progress on improving mitochondrial quality control and attenuating myocardial ischemia-reperfusion injury by melatonin].
Topics: Humans; Melatonin; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury | 2022 |
In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus.
Topics: Adenosine Diphosphate; Blood Platelets; Diabetes Mellitus, Type 2; Humans; Melatonin; Myocardial Inf | 2023 |
Remote ischemic preconditioning-induced late cardioprotection: possible role of melatonin-mitoKATP-H2S signaling pathway.
Topics: Animals; Ischemia; Ischemic Preconditioning; Ischemic Preconditioning, Myocardial; KATP Channels; Me | 2023 |
Melatonin attenuates inflammation and cardiac dysfunction in myocardial infarction by regulating the miRNA-200b-3p/high mobility group box chromosomal protein 1 axis.
Topics: Animals; Apoptosis; HMGB1 Protein; Hypoxia; Inflammation; Melatonin; MicroRNAs; Myocardial Infarctio | 2023 |
Melatonin and Nicotinamide Mononucleotide Attenuate Myocardial Ischemia/Reperfusion Injury via Modulation of Mitochondrial Function and Hemodynamic Parameters in Aged Rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Isolated Hea | 2020 |
Melatonin Ameliorates MI-Induced Cardiac Remodeling and Apoptosis through a JNK/p53-Dependent Mechanism in Diabetes Mellitus.
Topics: Animals; Anisomycin; Apoptosis; Cell Hypoxia; Cell Line; Cytoprotection; Diabetes Mellitus, Experime | 2020 |
Mitochondrial Oxidative Phosphorylation Function and Mitophagy in Ischaemic/Reperfused Hearts from Control and High-Fat Diet Rats: Effects of Long-Term Melatonin Treatment.
Topics: Animals; Antioxidants; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Male; Melatonin; Mit | 2020 |
Melatonin promotes cardiomyocyte proliferation and heart repair in mice with myocardial infarction via miR-143-3p/Yap/Ctnnd1 signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Animals, Newborn; Catenins; Cell Cycle; Cell Prolifer | 2021 |
Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection.
Topics: Animals; Apoptosis; Arrhythmias, Cardiac; Autophagy; Cardiotonic Agents; Cell Line; Cell Survival; M | 2021 |
Circadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nuclei.
Topics: Circadian Rhythm; Humans; Melatonin; Myocardial Infarction; Suprachiasmatic Nucleus | 2017 |
Reply to "Circadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nuclei".
Topics: Circadian Rhythm; Humans; Melatonin; Myocardial Infarction; Suprachiasmatic Nucleus | 2017 |
[Role of melatonin in calcium overload-induced heart injury].
Topics: Animals; Calcium; Caspase 3; Coloring Agents; Cytochromes c; Heart; Heart Injuries; L-Lactate Dehydr | 2017 |
Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply.
Topics: Heart; Humans; Melatonin; Myocardial Infarction; ST Elevation Myocardial Infarction | 2017 |
Poly(Lactide-Co-Glycolide)-Monomethoxy-Poly-(Polyethylene Glycol) Nanoparticles Loaded with Melatonin Protect Adipose-Derived Stem Cells Transplanted in Infarcted Heart Tissue.
Topics: Adipose Tissue; Allografts; Animals; Cell Survival; Melatonin; Myocardial Infarction; Nanoparticles; | 2018 |
Melatonin provides protection against heat stroke-induced myocardial injury in male rats.
Topics: Animals; Cardiotonic Agents; Heat Stroke; Inflammation; Male; Melatonin; Myocardial Infarction; Oxid | 2018 |
Pre-Treatment with Melatonin Enhances Therapeutic Efficacy of Cardiac Progenitor Cells for Myocardial Infarction.
Topics: Allografts; Animals; Melatonin; Mice; Myocardial Infarction; Myocardium; Stem Cell Transplantation; | 2018 |
Melatonin Attenuates Cardiac Reperfusion Stress by Improving OPA1-Related Mitochondrial Fusion in a Yap-Hippo Pathway-Dependent Manner.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Cell Cycle Proteins; Cells, Cultured; Dise | 2019 |
Plasma levels of melatonin in dilated cardiomyopathy.
Topics: Acute Disease; Aged; Cardiomyopathy, Dilated; Echocardiography; Female; Humans; Male; Melatonin; Mid | 2019 |
Infusion of Melatonin Into the Paraventricular Nucleus Ameliorates Myocardial Ischemia-Reperfusion Injury by Regulating Oxidative Stress and Inflammatory Cytokines.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cytokines; Disease Models, Animal; Inflammation Med | 2019 |
Function of the hypothalamo-neurohypophysial system in rats with myocardial infarction is modified by melatonin.
Topics: Animals; Arginine Vasopressin; Disease Models, Animal; Feedback, Physiological; Hypothalamo-Hypophys | 2012 |
Global left ventricular longitudinal strain is associated with decreased melatonin levels in patients with acute myocardial infarction: a two-dimensional speckle tracking study.
Topics: Aged; Biomarkers; Female; Heart Ventricles; Humans; Male; Melatonin; Middle Aged; Myocardial Infarct | 2013 |
Melatonin-induced augmentation of collagen deposition in cultures of fibroblasts and myofibroblasts is blocked by luzindole--a melatonin membrane receptors inhibitor.
Topics: Animals; Cells, Cultured; Cicatrix; Collagen; Fibroblasts; Heart; Male; Melatonin; Myocardial Infarc | 2013 |
Melatonin-induced glycosaminoglycans augmentation in myocardium remote to infarction.
Topics: Animals; Cells, Cultured; Collagen; Fibroblasts; Glycosaminoglycans; Heart Ventricles; Male; Melaton | 2013 |
[Cerebrovascular pharmacology of separate and combined vascular pathology of brain and heart].
Topics: Adamantane; Animals; Animals, Outbred Strains; Benzimidazoles; Bicuculline; Cerebral Cortex; Dopamin | 2014 |
Effects of intracoronary melatonin on ischemia-reperfusion injury in ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Animals; Antioxidants; Disease Models, Animal; Female; Magnetic Reso | 2016 |
Cardioprotection with melatonin in the acute myocardial infarction: awaiting results of MARIA trial?
Topics: Antioxidants; Humans; Melatonin; Myocardial Infarction; Randomized Controlled Trials as Topic | 2015 |
Letter in response to cardioprotection with melatonin in the acute myocardial infarction: Awaiting results of MARIA trial?
Topics: Humans; Melatonin; Myocardial Infarction | 2015 |
Melatonin protects ADSCs from ROS and enhances their therapeutic potency in a rat model of myocardial infarction.
Topics: Adipose Tissue; Angiogenesis Inducing Agents; Animals; Antioxidants; Apoptosis; Cell Survival; Cells | 2015 |
Effect of melatonin on oncosis of myocardial cells in the myocardial ischemia/reperfusion injury rat and the role of the mitochondrial permeability transition pore.
Topics: Animals; Male; Melatonin; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Tran | 2015 |
Role of melatonin, melatonin receptors and STAT3 in the cardioprotective effect of chronic and moderate consumption of red wine.
Topics: Animals; Cardiotonic Agents; Male; Melatonin; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial I | 2015 |
Melatonin facilitates adipose-derived mesenchymal stem cells to repair the murine infarcted heart via the SIRT1 signaling pathway.
Topics: Adipose Tissue; Animals; Female; Melatonin; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem | 2016 |
The impaired myocardial ischemic tolerance in adult offspring of diabetic pregnancy is restored by maternal melatonin treatment.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Dietary Supplements; Female; Melatonin; Mice; M | 2016 |
Melatonin prevents adverse myocardial infarction remodeling via Notch1/Mfn2 pathway.
Topics: Animals; Cardiotonic Agents; Drug Evaluation, Preclinical; Gene Expression; GTP Phosphohydrolases; J | 2016 |
[ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION: POSSIBILITIES FOR PREDICTING THE CLINICAL COURSE AT THE POST-HOSPITAL (6 AND 12 MONTHS) STAGE].
Topics: Acute Coronary Syndrome; Aged; Calcium; Creatinine; Electrocardiography; Female; Follow-Up Studies; | 2016 |
Melatonin alleviates postinfarction cardiac remodeling and dysfunction by inhibiting Mst1.
Topics: Animals; Apoptosis; Blotting, Western; Disease Models, Animal; In Situ Nick-End Labeling; Melatonin; | 2017 |
Melatonin attenuates postmyocardial infarction injury via increasing Tom70 expression.
Topics: Animals; Apoptosis; Disease Models, Animal; Gene Knockdown Techniques; Male; Melatonin; Mice; Mice, | 2017 |
Melatonin for cardioprotection in ST elevation myocardial infarction: are we ready for the challenge?
Topics: Angioplasty, Balloon, Coronary; Electrocardiography; Humans; Melatonin; Myocardial Infarction; ST El | 2017 |
Melatonin as an Agent for Cardioprotection in Patients with ST-Elevation Myocardial Infarction and Short Ischaemic Time.
Topics: Cardiovascular Diseases; Electrocardiography; Humans; Melatonin; Myocardial Infarction; Myocardial R | 2017 |
The protective effect of melatonin on nicotine-induced myocardial injury in newborn rats whose mothers received nicotine.
Topics: Animals; Animals, Newborn; Antioxidants; Dose-Response Relationship, Drug; Female; Glutathione Perox | 2008 |
Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions.
Topics: Adrenergic Antagonists; Animals; Colforsin; Cyclic AMP; Guanylate Cyclase; Heart; Indoles; Isoproter | 2008 |
Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.
Topics: Animals; Antioxidants; Calcium; Cardiolipins; Cardiovascular Agents; Cyclosporine; Cytochromes c; He | 2009 |
Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms.
Topics: Animals; Antioxidants; Aspartate Aminotransferases; Blotting, Western; Catalase; Glutathione; Glutat | 2010 |
Melatonin augments expression of the procollagen α1 (I) and α1 (III) genes in the infarcted heart scar of pinealectomized rats.
Topics: Animals; Cells, Cultured; Cicatrix; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type I | 2010 |
Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation.
Topics: Animals; Antioxidants; Cardiotonic Agents; Disease Models, Animal; Electrocardiography; Inflammation | 2010 |
Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Coronary Angiography; Coronary Circulat | 2010 |
Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection.
Topics: Animals; Blotting, Western; In Vitro Techniques; Male; Melatonin; Mice; Myocardial Infarction; Myoca | 2011 |
Pharmacological doses of melatonin reduce the glycosaminoglycan level within the infarcted heart scar.
Topics: Animals; Cells, Cultured; Cicatrix; Collagen; Glutathione; Glycosaminoglycans; Heart; Lipid Peroxida | 2011 |
Oxidative stress mediates cardiac infarction aggravation induced by intermittent hypoxia.
Topics: Animals; Antioxidants; Arterial Pressure; Cyclic N-Oxides; Ethidium; Hypoxia; Male; Melatonin; Myoca | 2013 |
Melatonin and cardiovascular disease: myth or reality?
Topics: Antioxidants; Cardiovascular Diseases; Circadian Rhythm; Humans; Melatonin; Myocardial Infarction | 2012 |
Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction.
Topics: Aged; Female; Humans; Male; Melatonin; Middle Aged; Myocardial Infarction; Prospective Studies; Ultr | 2012 |
Melatonin and cardioprotection in the acute myocardial infarction: a promising cardioprotective agent.
Topics: Cardiotonic Agents; Humans; Melatonin; Myocardial Infarction | 2012 |
Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin.
Topics: Animals; Antioxidants; Free Radical Scavengers; Male; Melatonin; Myocardial Infarction; Myocardial R | 2002 |
Decreased nocturnal melatonin levels during acute myocardial infarction.
Topics: Aged; Antioxidants; Circadian Rhythm; Darkness; Female; Glutathione Peroxidase; Humans; Light; Lipid | 2002 |
Protective effect of melatonin on myocardial infarction.
Topics: Animals; Antioxidants; Cardiotonic Agents; Gene Expression; Male; Melatonin; Mice; Mice, Inbred ICR; | 2003 |
Protective effects of melatonin against myocardial injury induced by isoproterenol in rats.
Topics: Animals; Cardiotonic Agents; Heart; Isoproterenol; Male; Melatonin; Myocardial Infarction; Myocardiu | 2003 |
Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction.
Topics: Circadian Rhythm; Female; Humans; Interleukin-6; Male; Melatonin; Middle Aged; Myocardial Infarction | 2004 |
Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes.
Topics: Animals; Cardiotonic Agents; Glutathione; Male; Malondialdehyde; Melatonin; Myocardial Infarction; O | 2005 |
Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction.
Topics: Adult; Aged; Circadian Rhythm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lipoproteins, LDL; | 2005 |
Short- and long-term effects of melatonin on myocardial post-ischemic recovery.
Topics: Animals; Cardiotonic Agents; In Vitro Techniques; Male; Melatonin; Myocardial Contraction; Myocardia | 2006 |
Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction.
Topics: C-Reactive Protein; Case-Control Studies; Circadian Rhythm; Electrocardiography; Female; Humans; Mal | 2006 |
Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction.
Topics: Aged; Biomarkers; C-Reactive Protein; Circadian Rhythm; Electrocardiography; Female; Follow-Up Studi | 2006 |
Nitric oxide synthase inhibition in rats: melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size.
Topics: Animals; Antioxidants; Blood Pressure; Hypertension; Male; Melatonin; Models, Animal; Myocardial Inf | 2006 |
Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction.
Topics: Aged; Case-Control Studies; Circadian Rhythm; Female; Humans; Male; Matrix Metalloproteinase 9; Mela | 2007 |
The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin.
Topics: Animals; Arylalkylamine N-Acetyltransferase; Blotting, Western; Coronary Vessels; Heart Ventricles; | 2007 |
Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Circadian Rhythm; Electrocardiography; Female; Free Rad | 2008 |
Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction.
Topics: Aged; Circadian Rhythm; Darkness; Female; Humans; Male; Melatonin; Myocardial Infarction; Vascular C | 2008 |
Long-term postinfarction melatonin administration alters the expression of DHPR, RyR2, SERCA2, and MT2 and elevates the ANP level in the rat left ventricle.
Topics: Animals; Atrial Natriuretic Factor; Calcium Channels, L-Type; Heart Ventricles; Male; Melatonin; Myo | 2008 |
Regulatory influence of melatonin on collagen accumulation in the infarcted heart scar.
Topics: Animals; Cells, Cultured; Cicatrix; Collagen; Fibroblasts; Gene Expression Regulation; Hydroxyprolin | 2008 |
Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart.
Topics: Animals; Male; Melatonin; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; | 2000 |